Lyell Immunopharma
LYEL
LYEL
69 hedge funds and large institutions have $81.9M invested in Lyell Immunopharma in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 34 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
39% less funds holding
Funds holding: 113 → 69 (-44)
62% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 34
81% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 53
Holders
69
Holding in Top 10
7
Calls
$243K
Puts
$165K
Top Buyers
| 1 | +$16.1M | |
| 2 | +$4.03M | |
| 3 | +$1.05M | |
| 4 |
RC
RBF Capital
San Francisco,
California
|
+$884K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$870K |
Top Sellers
| 1 | -$4.34M | |
| 2 | -$1.34M | |
| 3 | -$1.03M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$408K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$391K |
